Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PD-(L)1 checkpoint inhibitors to reach $58 Billion by 2025

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 23, 2024 11:03am

85 Views

Post# 36003279

RE:RE:PD-(L)1 checkpoint inhibitors to reach $58 Billion by 2025

Roche's acquisition of the marketing approval of tecentriq SC in Canada, could now be the catalyst for Roche to make its move on ONCY, thus prompting other bidders to escalate their M&A discussions with ONCY.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China